An updated patent review of isoflavones and isocoumarins (2018-2024).

IF 4.6 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2026-04-01 Epub Date: 2026-03-10 DOI:10.1080/13543776.2026.2642104

Hidayat Hussain

{"title":"An updated patent review of isoflavones and isocoumarins (2018-2024).","authors":"Hidayat Hussain","doi":"10.1080/13543776.2026.2642104","DOIUrl":null,"url":null,"abstract":"Introduction: It is well established that isocoumarins and isoflavones exhibit intriguing biological effects. During the period 2018-2024 isocoumarins and isoflavones chemistry has attracted attention due to their biological and pharmaceutical properties.Areas covered: This review focuses on patents relating to the therapeutic properties of isocoumarins and isoflavones between 2018 and 2024. The latest patented studies of isocoumarin and isoflavone are summarized by using the keywords 'isocoumarin' and 'isoflavone' in SciFinder, PubMed, and Google Patents databases in the year from 2018 to 2024.Expert opinion: A wide range of important pharmaceutical properties are exhibited by isocoumarins and isoflavones and their synthetic analogs. In addition, isocoumarins and isoflavones have the potential to couple with other biologically active molecules, synergistically enhancing delivery and biological effects. In addition, scientists should direct their efforts toward the synthesis of halo-substituted and functionalized heterocyclic ring derivatives of isocoumarins and isoflavones, with a view to obtaining lead compounds. The lack of pharmacology and pharmacokinetics data along with in vivo studies for isocoumarins and isoflavones, prevents effective regulatory decisions from being proposed. In addition, detailed efficacy studies in well-established disease models are required to determine the clinical effects of isocoumarins and isoflavones.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"299-309"},"PeriodicalIF":4.6000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2026.2642104","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: It is well established that isocoumarins and isoflavones exhibit intriguing biological effects. During the period 2018-2024 isocoumarins and isoflavones chemistry has attracted attention due to their biological and pharmaceutical properties.

Areas covered: This review focuses on patents relating to the therapeutic properties of isocoumarins and isoflavones between 2018 and 2024. The latest patented studies of isocoumarin and isoflavone are summarized by using the keywords 'isocoumarin' and 'isoflavone' in SciFinder, PubMed, and Google Patents databases in the year from 2018 to 2024.

Expert opinion: A wide range of important pharmaceutical properties are exhibited by isocoumarins and isoflavones and their synthetic analogs. In addition, isocoumarins and isoflavones have the potential to couple with other biologically active molecules, synergistically enhancing delivery and biological effects. In addition, scientists should direct their efforts toward the synthesis of halo-substituted and functionalized heterocyclic ring derivatives of isocoumarins and isoflavones, with a view to obtaining lead compounds. The lack of pharmacology and pharmacokinetics data along with in vivo studies for isocoumarins and isoflavones, prevents effective regulatory decisions from being proposed. In addition, detailed efficacy studies in well-established disease models are required to determine the clinical effects of isocoumarins and isoflavones.

查看原文本刊更多论文

异黄酮和异香豆素专利更新审查（2018-2024）。

引言：异香豆素和异黄酮具有有趣的生物学效应。在2018-2024年期间，异香豆素和异黄酮的生物学和药学性质引起了人们的关注。涵盖领域：本综述重点关注2018年至2024年间与异香豆素和异黄酮治疗特性相关的专利。以检索词“isocoumarin”和“isoflavone”在SciFinder、PubMed、谷歌Patents等数据库中检索到的2018 - 2024年有关异香豆素和异黄酮的最新专利研究。专家意见：异香豆素和异黄酮及其合成类似物具有广泛的重要药物特性。此外，异香豆素和异黄酮有可能与其他生物活性分子偶联，协同增强递送和生物效应。此外，科学家应致力于合成异香豆素和异黄酮的卤代和功能化杂环衍生物，以期获得先导化合物。由于缺乏药理学和药代动力学数据以及异香豆素和异黄酮的体内研究，因此无法提出有效的监管决策。此外，还需要在已建立的疾病模型中进行详细的疗效研究，以确定异香豆素和异黄酮的临床效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.